BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chhatwal J, Chen Q, Ayer T, Bethea ED, Kanwal F, Kowdley KV, Wang X, Roberts MS, Gordon SC. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Aliment Pharmacol Ther 2018;47:1023-31. [PMID: 29377245 DOI: 10.1111/apt.14527] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Chhatwal J, Chen Q, Aggarwal R. Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling. Infect Dis Clin North Am 2018;32:461-80. [PMID: 29778266 DOI: 10.1016/j.idc.2018.02.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
2 Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, María Morillas R, Rosales JM, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turnes J, González-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Iñarrairaegui M, Pascasio JM, Esteban R, Mariño Z, Buti M. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J Hepatol 2019;71:666-72. [PMID: 31203153 DOI: 10.1016/j.jhep.2019.06.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
3 Frías M, Rivero-juárez A, Machuca I, Camacho Á, Rivero A. The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. Expert Review of Precision Medicine and Drug Development 2020;5:253-63. [DOI: 10.1080/23808993.2020.1764346] [Reference Citation Analysis]
4 Marascio N, Quirino A, Barreca GS, Galati L, Costa C, Pisani V, Mazzitelli M, Matera G, Liberto MC, Focà A, Torti C. Discussion on critical points for a tailored therapy to cure hepatitis C virus infection. Clin Mol Hepatol 2019;25:30-6. [PMID: 30669818 DOI: 10.3350/cmh.2018.0061] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
5 Villani R, Monami M, Di Cosimo F, Fioravanti G, Mannucci E, Vendemiale G, Serviddio G. Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis. J Viral Hepat 2019;26:1249-56. [PMID: 31243849 DOI: 10.1111/jvh.13169] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
6 Bourlière M, Pietri O, Castellani P, Oules V, Adhoute X. Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road? Therap Adv Gastroenterol 2018;11:1756284818812358. [PMID: 30574189 DOI: 10.1177/1756284818812358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Viral resistance in HCV infection. Curr Opin Virol 2018;32:115-27. [PMID: 30439589 DOI: 10.1016/j.coviro.2018.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
8 Park H, Lo-Ciganic WH, Huang J, Wu Y, Henry L, Peter J, Sulkowski M, Nelson DR. Machine learning algorithms for predicting direct-acting antiviral treatment failure in chronic hepatitis C: An HCV-TARGET analysis. Hepatology 2022. [PMID: 35034373 DOI: 10.1002/hep.32347] [Reference Citation Analysis]
9 Doyle JS, Scott N, Sacks-Davis R, Pedrana AE, Thompson AJ, Hellard ME; Eliminate Hepatitis C Partnership. Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia. Aliment Pharmacol Ther 2019;49:1223-9. [PMID: 30908706 DOI: 10.1111/apt.15210] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
10 Chhatwal J, Chen Q, Bethea ED, Hur C, Spaulding AC, Kanwal F. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Aliment Pharmacol Ther 2019;50:66-74. [PMID: 31115920 DOI: 10.1111/apt.15291] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
11 Bourlière M, Pietri O. Hepatitis C virus therapy: No one will be left behind. Int J Antimicrob Agents 2019;53:755-60. [PMID: 30605721 DOI: 10.1016/j.ijantimicag.2018.12.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
12 Boeke CE, Hiebert L, Waked I, Tsertsvadze T, Sharvadze L, Butsashvili M, Zakalashvili M, Naing W, Gupta N, Kateera F, McClure C, Ward JW, Ramers CB. Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes from National Treatment Programs in Three Low- and Middle-Income Countries. Clin Infect Dis 2021:ciab461. [PMID: 34014252 DOI: 10.1093/cid/ciab461] [Reference Citation Analysis]
13 Gordon S, Lee J, Smith N, Dieterich D. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States. Expert Rev Pharmacoecon Outcomes Res 2020;20:251-7. [PMID: 31204882 DOI: 10.1080/14737167.2019.1629291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
14 Darweesh SK, Elsaeed K, Omar H, El Raziky M, Elakel W, Elserafy M, Ismail SA, Gomaa AA, Mehrez M, El Kassas M, Abdullah M, Shaker MK, Esmat G, El Shazly Y, Doss W, Waked I. High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study. Expert Rev Gastroenterol Hepatol 2019;13:907-14. [PMID: 31173527 DOI: 10.1080/17474124.2019.1629287] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Marshall AD, Pawlotsky J, Lazarus JV, Aghemo A, Dore GJ, Grebely J. The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat. Journal of Hepatology 2018;69:1188-96. [DOI: 10.1016/j.jhep.2018.06.016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 13.3] [Reference Citation Analysis]
16 Frias M, Rivero-Juárez A, López-López P, Rivero A. Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients. Pharmacogenomics 2018;19:979-95. [PMID: 29992850 DOI: 10.2217/pgs-2018-0046] [Reference Citation Analysis]
17 Onofrio FQ, Cooper C, Borgia SM, Vachon ML, Ramji A, Lilly LB, Wong A, Booth J, Sattar I, Morales H, Lee S, Conway B, Feld JJ. Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry. Clin Infect Dis 2021;72:e799-805. [PMID: 33677545 DOI: 10.1093/cid/ciaa1510] [Reference Citation Analysis]
18 Guntipalli P, Pakala R, Kumari Gara S, Ahmed F, Bhatnagar A, Endaya Coronel MK, Razzack AA, Solimando AG, Thompson A, Andrews K, Enebong Nya G, Ahmad S, Ranaldo R, Cozzolongo R, Shahini E. Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastroenterol Belg 2021;84:637-56. [PMID: 34965046 DOI: 10.51821/84.4.015] [Reference Citation Analysis]
19 Balakrishnan M, Kanwal F. The HCV Treatment Cascade: Race Is a Factor to Consider. J Gen Intern Med 2019;34:1949-51. [PMID: 31342332 DOI: 10.1007/s11606-019-04962-3] [Reference Citation Analysis]